



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

## Open Clinical Trials

January 2026

**To refer a patient, please contact the disease specific nurse navigator directly to schedule a visit with one of our providers.**

**Please note that slot status may vary over time.**

**For more information regarding trials at the University of Colorado, please visit:**  
<https://researchstudies.cuanschutz.edu/>

### Jump to Cancer Types

- [Breast](#)
- [Cutaneous](#)
- [Gastrointestinal](#)
- [Genitourinary](#)
- [Gynecologic](#)
- [Head and Neck](#)
- [Hematology](#)
- [Neuro-Oncology](#)
- [Phase 1, Expansion, Molecular Studies \(POEMs\)](#)
- [Radiation Oncology](#)
- [Sarcoma](#)
- [Thoracic \(Lung\)](#)

[Common Eligibility Criteria for Clinical Trials](#)

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

[Satellite Site Contacts](#)



Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Sara Johnson, BSN, RN	Sara.johnson@uchealth.org	Phone: 720-848-9237 Fax: 720-848-1774
Physician Leads	Email	Phone
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	

Metastatic Breast Cancer			
Study Name	Patients	NCT#	Sites
Phase I study of OP-1250 (Palazestrant) with ribociclib, alpelisib, everolimus, or atirmociclib (22-1277)	Advanced/Metastatic ER+, HER2- breast cancer	<a href="#">NCT05508906</a>	AMC
PRE-I-SPY Phase 1/1b Platform, PRE-Investigation of Serial Studies (24-1242)	Previously treated metastatic breast cancer	<a href="#">NCT05868226</a>	AMC
Phase 3 trial of saruparib (PARP1i) plus camizestrant (SERD) vs MD choice of CDK4/6 plus endocrine therapy (24-1711)	ER+, HER2-, BRCA1, BRCA2 or PALB2 mutations	<a href="#">NCT06380751</a>	AMC
Phase 3 Study of MK-2870 (Sac-TMT, ADC) +/- pembromizumab vs physician's choice therapy (24-1416)	HR+/HER2-negative metastatic breast cancer	<a href="#">NCT06312176</a>	AMC CCMC HRH
Phase 2 trial of nab-paclitaxel, durvalumab, tremelimumab +/- vaccine (19-0013)	1L metastatic TNBC	<a href="#">NCT03606967</a>	AMC
Phase 2 study of tucatinib, eribulin, trastuzumab (22-1407)	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT05458674</a>	AMC
PIKture-01 Phase 1 OKI-219 (mutant selective PI3K H1047R inhibitor) (24-0016)	Previously treated metastatic solid tumors with PI3K H1047R mutation	<a href="#">NCT06239467</a>	AMC
Phase 1 study of XMT-2056 (immune conjugate). <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (24-1517)	Previously treated metastatic HER2+ or HER2 low breast or Gastric/GE	<a href="#">NCT05514717</a>	AMC
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi) (21-3077)	1L metastatic HR+HER2- breast cancer	<a href="#">NCT04862663</a>	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer	<a href="#">NCT05768139</a>	AMC (POEMs)
Phase 3 study OP-1250 (SERD) (23-2036)	Metastatic HR+HER2-	<a href="#">NCT06016738</a>	AMC, HRH, CCMC, LT
Phase 3 study of zanidatamab (HER2 bispecific ab) + standard therapy v. trastuzumab + standard therapy (24-1635)	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT06435429</a>	AMC, HRH, CCMC
DYNASTY-Breast02: Phase 3 DB-1303 (ADC) v. standard therapy (24-0384)	Metastatic HR+ HER2 low	<a href="#">NCT06018337</a>	AMC, LT, HRH, CCMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Phase 2 study of alisertib (AurAi) + endocrine therapy (24-1686)	Metastatic HR+HER2-	<a href="#">NCT06369285</a>	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer	<a href="#">NCT06014658</a>	AMC (POEMs)
CDK4/6 Inhibitor dosing knowledge (CDK) study (24-1798)	Metastatic breast cancer in older adults	<a href="#">NCT06377852</a>	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)
Phase 2 study of zelenectide (ADC) (25-0193)	NECTIN4 Amplified Advanced HR+ HER2- or TNBC	<a href="#">NCT06840483</a>	AMC
Phase II study of utidelone (UTD1) + capecitabine (25-0715)	HER2-negative Metastatic Breast Cancer Patients with Brain Metastases	<a href="#">NCT06764940</a>	AMC
<b>Early-Stage Breast Cancer</b>			
ISPY2.2 neoadjuvant study (10-0374)	Stage II-III Breast cancer	<a href="#">NCT01042379</a>	AMC, LT, HRH, CCMC
DARE: Phase 2 trial of ctDNA-guided treatment (20-2773)	High risk HR+HER2-	<a href="#">NCT04567420</a>	AMC, LT, HRH, CCMC
OFFSET: Phase 3 study of chemotherapy v. ovarian suppression (23-2461)	Premenopausal HR+HER2-breast cancer	<a href="#">NCT05879926</a>	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR (23-1255)	TNBC with pCR to neoadjuvant therapy	<a href="#">NCT05812807</a>	AMC, LT, HRH
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0M0 breast cancer (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="#">NCT03488693</a>	AMC, CCMC, HRH, LT (RT Group)
NRG-BR007: DEBRA: Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer (21-4582)	Stage I, HR+, HER2- breast cancer with Oncotype RS $\leq$ 18	<a href="#">NCT04852887</a>	AMC, CCMC, HRH (RT Group)
S2206: Phase 3 trial of neoadjuvant durvalumab (PD-L1i) plus chemo vs chemo alone (24-0401)	MammaPrint ultrahigh ER/PR+, HER2-	<a href="#">NCT06058377</a>	AMC, LT, HRH, CCMC
CAMBRIA-2: Phase 3 trial of adjuvant camizestrant (SERD) vs standard endocrine therapy (24-1414)	ER+/HER2-; intermediate-high or high risk for recurrence following definitive treatment, currently NED	<a href="#">NCT05952557</a>	AMC, HRC, CCMC
A012301 LoTam: A randomized, phase III trial of low-dose tamoxifen (25-0681)	Molecular low-risk early-stage breast cancer (T2-T4, N0, M0 or T1-T3, N1-2, M0, or Tx N1-2, M0)	<a href="#">NCT06671912</a>	AMC CCMC LT HRH
S2212 SCARLET: Shorter Anthracycline-Free Chemo Immunotherapy in Early TNBC (23-2438)	Early Stage TNBC	<a href="#">NCT05929768</a>	AMC, CCMC LT HRH



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Cutaneous Oncology**  
**Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Nurse navigator	melanoma@ucHealth.org	Phone: 720-848-0505 Fax: 720-848-0614
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	

**High-Risk Resected Melanoma**

**No current trials available**

**Advanced Melanoma**

Phase 2/3 study of LNS8801 (GPER agonist) +/- without pembrolizumab (25-0336)	Treatment refractory, unresectable melanoma	<a href="#">NCT06624644</a>	AMC
Phase 3 trial of Lifileucel (LN-144 tumor infiltrating lymphocyte) + pembro vs pembro alone (24-0982)	Untreated, unresectable or metastatic melanoma	<a href="#">NCT05727904</a>	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L PD-L1+ melanoma 2L PD-L1+ melanoma	<a href="#">NCT05533697</a>	AMC (POEMs)
IGNYTE-3: Phase 3 trial of vusolimogene oderparepvec (oncolytic virus) + nivolumab v. treatment of physician's choice (24-1672)	Advanced melanoma progressed on Anti-PD-1 and Anti-CTLA-4	<a href="#">NCT06264180</a>	AMC
Phase 3 trial of fianlimab + cemiplimab vs relatlimab (LAG-3i) and nivolumab (24-1713)	Unresectable or metastatic melanoma	<a href="#">NCT06246916</a>	AMC
PRISM-MEL-301: Phase 3 trial of nivolumab +/- IMC-F106C (PRAME x CD3 bispecific) (23-2225)	1L advanced melanoma HLA-A*02:01-positive	<a href="#">NCT06112314</a>	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	<a href="#">NCT05355701</a>	AMC (POEMs)

**Neoadjuvant or Resectable Melanoma**

Phase 2 peri-operative study of fianlimab + cemiplimab v. Anti-PD1 alone (24-2030)	Resectable Stage 3 and 4 Melanoma	<a href="#">NCT06190951</a>	AMC
--	-----------------------------------	-----------------------------	-----

**Uveal Melanoma**

DAR-UM-2: Darovasertib (PKC $\iota$ ) + crizotinib v. standard therapy (24-0171)	1L HLA-A2 negative metastatic uveal melanoma	<a href="#">NCT05987332</a>	AMC
Phase 2/3 Study of RP2 (oncolytic virus) + nivolumab v. ipilimumab + nivolumab (25-0004)	Immune checkpoint inhibitor-naïve metastatic uveal melanoma; no more than 2 lines of systemic therapy	<a href="#">NCT06581406</a>	AMC

**Merkel Cell Carcinoma, Squamous Cell Carcinoma**

**No current trials available**

**Advanced Cutaneous Malignancies in Transplant Recipients**

Phase 1b/2 study of RP1 (oncolytic virus) (19-2987)	Solid organ or hematopoietic cell transplant recipient	<a href="#">NCT04349436</a>	AMC
---	--	-----------------------------	-----



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, CRC, HNSCC	<a href="#">NCT04626635</a>	AMC (POEMs)
--	---	-----------------------------	-------------



### Gastrointestinal Oncology Anschutz Medical Campus (AMC)

Nurse Navigators	Email	Phone
Jamie Peterson	Jamie.Peterson@uchealth.org	Phone: 720-848-2636
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Sarah Reynolds	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physicians	Email	Phone
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	

### Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers

Phase 3 study of rilvestomig (bispecific ab) + fluoropyrimidine + trastuzumab deruxtecan v. trastuzumab, chemotherapy + pembrolizumab (ARTEMIDE-Gastric01/25-0646) (25-0646)	1L HER2 gastric cancer	<a href="#">NCT06764875</a>	AMC
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
Phase 1 study of XMT-2056 (immune conjugate). <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (24-1517)	Previously treated metastatic HER2+ or HER2 low breast or Gastric/GE	<a href="#">NCT05514717</a>	AMC
Phase 1 study of TJ033721 in metastatic gastric, GE and esophageal adenocarcinoma (21-3254)	1L metastatic gastric, GE, and esophageal adeno ca positive for CLDN18.2	<a href="#">NCT04900818</a>	AMC
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8ab) + toripalimab +/- other treatments (25-1556)	2L Gastric, GEJ and Esophageal Adenocarcinoma and 2L esophageal squamous cell carcinoma	<a href="#">NCT06657144</a>	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)

### Early-Stage Colorectal Cancer (CRC)

CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease (22-0916)	Stage IIIA/B MSS colon adenocarcinoma following curative resection	<a href="#">NCT05174169</a>	AMC, LT, HRH, CCMC
---	--	-----------------------------	--------------------

### Metastatic Colorectal Cancer (CRC)

Phase I trial of AWN003694 + cetuximab + encorafenib (25-0300)	Refractory BRAF V600E metastatic CRC	<a href="#">NCT06102902</a>	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT
OrigAMI-3: Phase 3 study of FOLFIRI + amavantamab v cetuximab/bevacizumab in metastatic CRC (24-2380)	2L metastatic CRC KRAS/NRAS and BRAF WT	<a href="#">NCT06750094</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC (21-3774)	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	<a href="#">NCT04929223</a>	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (22-0697)	Previously treated metastatic CRC, GCC+, MSS	<a href="#">NCT05319314</a>	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	<a href="#">NCT05355701</a>	AMC (POEMs)
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
AE2222: PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets (24-0029)	Unresectable liver metastatic CRC	<a href="#">NCT05863195</a>	AMC
Phase 1 study of JNJ-89402638 (bispecific ab) for metastatic CRC (24-1600)	3L+ unresectable metastatic CRC	<a href="#">NCT06663319</a>	AMC
Phase 1 study of BI1831169 (oncolytic virus) +/- ezabenlimab (anti-PD-1) in advanced solid GI tumors (23-2048)	Advanced or metastatic GI tumors with no standard therapies	<a href="#">NCT05155332</a>	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8) + toripalimab with or without other treatments in participants with advanced or metastatic solid tumors (25-1556)	4L + CRC	<a href="#">NCT06657144</a>	AMC
<b>Liver Cancer</b>			
Phase 1b/2 study of multiple immunotherapy based treatment combinations (24-1787)	Locally advanced/metastatic /unresectable HCC; no prior treatment	<a href="#">NCT04524871</a>	AMC, HRH, CCMC
Phase 1b/2 study of TTI-101 in advanced or metastatic HCC (22-1621)	1-3L Unresectable, locally advanced or metastatic HCC	<a href="#">NCT05440708</a>	AMC
<b>Biliary Tract Cancer</b>			
Protocol 10608, A phase II trial of durvalumab with gemcitabine and cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma (24-0573)	Resectable intrahepatic cholangiocarcinoma	<a href="#">NCT06050252</a>	AMC
Phase 1/2 study of M3814 + avelumab with hypofractionated radiation in metastatic hepatobiliary malignancies (23-2261)	2L+ metastatic or locally advanced cholangio or gallbladder carcinoma	<a href="#">NCT04068194</a>	AMC
Phase 1/2 study of patritumab deruxtecan (ADC) (24-1883)	2L + Biliary Tract Cancer	<a href="#">NCT06596694</a>	AMC
<b>Pancreatic Cancer</b>			
Intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma (24-2111)	Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis	<a href="#">NCT07030283</a>	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma (20-2093)	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	<a href="#">NCT04172532</a>	AMC
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
Phase 1b study of ATP150/2 (vaccine), VSV-GP154 (viral vector) and ezabenlimab (ICI) in pancreatic cancer (23-1329)	Metastatic pancreatic ductal adenocarcinoma KRAS G12D/G12V mutation	<a href="#">NCT05846516</a>	AMC
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer (23-0613)	2-3L metastatic or unresectable pancreatic ductal adenocarcinoma	<a href="#">NCT05685602</a>	AMC
<b>Neuroendocrine Cancers</b>			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors (21-3552)	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	<a href="#">NCT04919226</a>	AMC
NET Retreat: Phase 2 study of 177Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine (23-1917)	Metastatic grade 1/2 midgut neuroendocrine tumors	<a href="#">NCT05773274</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Genitourinary Oncology  
Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Laura Graham, MD	Laura.graham@cuanschutz.edu	
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	

**Localized Prostate Cancer**

<b>Study Name</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations (23-2420)	Localized prostate cancer with germline BRCA1/2 mutation	<a href="#">NCT05806515</a>	AMC
NRG GU010: Genomic risk stratification for unfavorable intermediate risk localized prostate cancer (22-0175)	Localized prostate cancer unfavorable intermediate risk	<a href="#">NCT05050084</a>	AMC (RT Group)
Pragmatic study of metformin v. lifestyle mods (19-1536)	Localized prostate cancer	<a href="#">NCT05515978</a>	AMC

**Metastatic Prostate Cancer**

S1802: SST +/- surgery or radiation (18-2252)	Metastatic hormone sensitive prostate cancer	<a href="#">NCT03678025</a>	AMC
NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	<a href="#">NCT05053152</a>	AMC, HRH (RT Group)
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro (21-3724)	De novo and treatment emergent neuroendocrine/small cell prostate cancer	<a href="#">NCT02861573</a>	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0350)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	<a href="#">NCT06136624</a>	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0742)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	<a href="#">NCT06136650</a>	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343 (23-1990)	Metastatic castration-resistant prostate cancer	<a href="#">NCT06095089</a>	AMC
Phase 1b/2a study of pocenbrodib alone or in combination with abiraterone acetate, olaparib, or 177Lu-PSMA-617 (24-2278)	Metastatic castration-resistant Prostate Cancer	<a href="#">NCT06785636</a>	AMC
CCTG-PR26 - Randomized phase 3 clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors (TRIPLE-SWITCH) (25-0680)	Metastatic castration-sensitive prostate cancer and suboptimal PSA response	<a href="#">NCT06592924</a>	AMC CCMC LT HRH

**Bladder Cancer**

Phase 2 study of intravesicular instillation of TARA-002 (24-1264)	High grade non-muscle invasive bladder cancer	<a href="#">NCT05085990</a>	AMC
--	---	-----------------------------	-----



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

EA8192 Preoperative durvalumab and/or chemo (21-3855)	Upper tract urothelial cancer	<a href="#">NCT04628767</a>	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance (24-0700)	Muscle invasive bladder cancer or upper tract urothelial cancer after surgery	<a href="#">NCT05987241</a>	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors (18-1651)	2L metastatic bladder cancer	<a href="#">NCT03375307</a>	AMC
S1937: Eribulin + gemcitabine v. standard therapy (22-0927)	3L+ metastatic bladder cancer post PD1i	<a href="#">NCT04579224</a>	AMC
<b>Kidney Cancer</b>			
SAMURAI: Phase 2 study of SABR in patients receiving immunotherapy (24-2480)	Metastatic unresectable RCC	<a href="#">NCT05327686</a>	AMC, LT, HRH, CCMC
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus (22-1669)	Neoadjuvant therapy for RCC with tumor thrombus	<a href="#">NCT05969496</a>	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors (18-1651)	2L metastatic kidney cancer	<a href="#">NCT03375307</a>	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC (24-0745)	2L+ metastatic clear cell RCC	<a href="#">NCT06234605</a>	AMC
STRIKE/A032201: Study of short term intensified pembrolizumab + tivozanib for high-risk renal cell carcinoma (25-0682)	Clear cell RCC following complete resection	<a href="#">NCT06661720</a>	AMC HRH CCMC LT
<b>Penile Cancer</b>			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND (17-1515)	Penile cancer	<a href="#">NCT02305654</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Gynecologic Oncology Anschutz Medical Campus (AMC)			
Nurse Navigator	Email	Phone	
Clinic schedulers	-	Phone: 303-724-2066	
Physician	Email	Phone	
Brad Corr, MD	Bradley.corr@cuanschutz.edu		
Ovarian Cancer - Frontline			
Study	Patients	NCT#	Sites
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer (23-2189)	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	<a href="#">NCT05659381</a>	AMC
Ovarian Cancer - Maintenance			
GOG 3072 TETON: Phase 1b study of ZN-c3 (Wee1i) + chemo or bevacizumab in ovarian cancer (22-0890)	1-2L platinum sensitive ovarian, primary peritoneal, fallopian tube cancer no BRCA mutation	<a href="#">NCT04516447</a>	AMC
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer (22-0384)	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	<a href="#">NCT05887609</a>	AMC
NRG-GY036: Phase 3 trial of one vs. two years maintenance olaparib, +/- bevacizumab (25-0399)	BRCA1/2 mutated or HRD+ ovarian cancer following response to 1L platinum-based chemotherapy	<a href="#">NCT06580314</a>	AMC CCMC HRH
Ovarian Cancer - Recurrent			
FONTANA: Phase 1/2a study of AZD5335 (ADC folate receptor + TOP11) in solid tumors (23-2128)	Platinum-resistant or platinum-sensitive ovarian cancer	<a href="#">NCT05797168</a>	AMC
VOLAстра: Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	<a href="#">NCT05902988</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
A Phase 1b study of psilocybin assisted psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission (23-1455)	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	<a href="#">NCT06430541</a>	AMC
GCT1184-02 (GOG-3107): A Phase 3 study of rinatabart sesutecan (Rina-S) v. TPC (25-0457)	Platinum-resistant ovarian cancer	<a href="#">NCT06619236</a>	AMC
Phase I study of CLK/DYRK (Cirtuvivint) + olaparib in BRCA/HRD	Platinum-resistant ovarian cancer with 1-3 prior lines of therapy.	<a href="#">NCT06856499</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

platinum resistant ovarian cancer (24-1749)	BRCA or HRD + with prior parp inhibitor.		
<b>Ovarian Cancer – Low Grade</b>			
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor talazoparib, in Patients with molecularly-selected solid tumors (ComBET) (23-0145)	HRD tumors with prior PARPi use as immediate prior therapy	<a href="#">NCT05327010</a>	AMC (POEMs)
<b>Endometrial Cancer - Presurgical</b>			
<b>No current studies available</b>			
<b>Endometrial Cancer - Frontline</b>			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- hylecta or phesgo in HER2+ endometrial cancer (22-1764)	1L Stage I-IV endometrial serous carcinoma, carcinosarcoma, or other histology HER2+	<a href="#">NCT05256225</a>	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early stage endometrial cancer (24-1417)	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	<a href="#">NCT06388018</a>	AMC
<b>Endometrial Cancer - Recurrent</b>			
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/- gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivot oncosignature (23-0115)	Up to 2L in recurrent setting: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivot Oncosignature Status	<a href="#">NCT05548296</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
<b>Uterine Leiomyosarcoma</b>			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma (24-0041)	Newly diagnosed ER+ uterine leiomyosarcoma	<a href="#">NCT05649956</a>	AMC, HRH
<b>BRCA Mutation Carriers</b>			
SOROC: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers (20-2079)	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	<a href="#">NCT04251052</a>	AMC, HRH



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

### Head and Neck Cancer Anschutz Medical Campus (AMC)

Nurse Navigator	Email	Phone
Jamie Peterson	<a href="mailto:Jamie.Peterson@ucHealth.org">Jamie.Peterson@ucHealth.org</a>	Phone: 720-848-2636
Natalya Veneychuk	<a href="mailto:Natalya.Veneychuk@ucHealth.org">Natalya.Veneychuk@ucHealth.org</a>	Phone: 720-848-5456
Physician	Email	Phone
Antonio Jimeno, MD, PhD	<a href="mailto:Antonio.jimeno@cuanschutz.edu">Antonio.jimeno@cuanschutz.edu</a>	

### Head and Neck Cancer

Study Name	Patients	NCT#	Sites
Phase 1b/2 study of NT219 in combination with pembrolizumab or cetuximab (24-0689)	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	<a href="#">NCT06919666</a>	AMC, HRH
Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, CRC, HNSCC	<a href="#">NCT04626635</a>	AMC (POEMs)
FORTIFI-HN010: Phase 2/3 study of ficerafusp alfa (BCA101) v. placebo + pembrolizumab (25-0122)	1L PD-L1-positive, recurrent or metastatic HNSCC	<a href="#">NCT06788990</a>	AMC
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC (23-2332)	Unresected locally advanced HNSCC who have not progressed following definitive concurrent chemoRT	<a href="#">NCT06129864</a>	AMC, HRH
OrigAMI-4: Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC (24-0472)	Recurrent or metastatic HNSCC	<a href="#">NCT06385080</a>	AMC
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC (24-1630)	Locoregionally recurrent refractory or oligometastatic HNSCC	<a href="#">NCT06211335</a>	AMC, HRH
NRG-HN010: Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer (22-2363)	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	<a href="#">NCT05408845</a>	AMC, HRH
EA3231: Phase 3 study of BRAF-targeted therapy v. cabozantinib in RAI-refractory differentiated thyroid cancers with BRAF V600 E mutation (24-2273)	Advanced RAI-refractory differentiated thyroid cancers with BRAF V600 E mutation	<a href="#">NCT06475989</a>	AMC, HRH



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Hematology Clinical Trials Unit  
Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b> UCH-BDC Intake Team	<b>Email</b> <a href="mailto:UCH-BDCIntakeTeam20181018184924@ucHealth.org">UCH-BDCIntakeTeam20181018184924@ucHealth.org</a>	<b>Phone</b> 720-848-2595
<b>Doc Line Phone:</b> 720-848-2628 (doc line)		
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
<b>Leukemia:</b> Dan Polleyea, MD	Daniel.polleyea@cuanschutz.edu	720-848-8084
<b>Cell Therapy/Stem Cell Transplant:</b> Jon Gutman, MD	Jonathan.gutman@cuanschutz.edu	720-848-0220
<b>Lymphoma:</b> Manali Kamdar, MD	Manali.kamdar@cuanschutz.edu	720-848-0752
<b>Multiple Myeloma:</b> Dan Sherbenou, MD, PhD	Daniel.sherbenou@cuanschutz.edu	303-724-9520
<b>Benign Heme and MPNs:</b> Brandon McMahon, MD	Brandon.mcmahon@cuanschutz.edu	720-848-8868

**Leukemia**

<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
Phase 1b study to evaluate eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (PI: McMahon, C/24-2332)	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	<a href="https://clinicaltrials.gov/ct2/show/NCT06533761">NCT06533761</a>	AMC
Phase I study of SNDX-5613 in patients with relapsed/refractory leukemias including those harboring an MLL/KMT2A gene rearrangement or nucleophosmin1 (NPM1) Mutation (PI: McMahon C/ 22-1050)	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	<a href="https://clinicaltrials.gov/ct2/show/NCT04065399">NCT04065399</a>	AMC
Phase I study of CD19 directed CAR T Cells in adult patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with minimal residual disease (MRD) positivity at first complete remission (PI: Schwartz/22-0054)	Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2	<a href="https://clinicaltrials.gov/ct2/show/NCT05535855">NCT05535855</a>	AMC
Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent/24-0178)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	<a href="https://clinicaltrials.gov/ct2/show/NCT06429449">NCT06429449</a>	AMC
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogenic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	<a href="https://clinicaltrials.gov/ct2/show/NCT05473910">NCT05473910</a>	AMC



A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab vs. venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy (PI: McMahon/24-0685)	Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts). Previously untreated AML. Deemed unfit for intensive therapy.	<a href="#">NCT06384261</a>	AMC
Study of cladribine + venetoclax after failure of venetoclax + hypomethylating agent in monocytic AML (PI: McMahon/23-0273)	Ages $\geq$ 18; Relapsed/Refractory AML; ECOG of $\leq$ 2	<a href="#">NCT06232655</a>	AMC
KO-MEN-007: Phase 1 study of venetoclax/azacitidine or venetoclax + ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) + ziftomenib for AML (PI: McMahon/23-0061)	Ages $\geq$ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of $\leq$ 2	<a href="#">NCT05735184</a>	AMC
MO-TRANS) Phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment (24-0936)	acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT)	<a href="#">NCT05429632</a>	AMC
<b>Myelodysplastic Syndrome Trials</b>			
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogenic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	<a href="#">NCT05473910</a>	AMC
<b>Lymphoma</b>			
Phase I study of patient-derived multi-tumor associated antigen specific T-cells (MT-601) in patients with relapsed/refractory non- hodgkin lymphoma (PI:Kamdar/23-0056)	Diagnosis of NHL, HL or CLL; ECOG or zero or 1; adequate organ function	<a href="#">NCT05798897</a>	AMC
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (PI: Milgrom/24-2065)	Newly diagnosed Stage I and II classic Hodgkins Lymphoma	<a href="#">NCT05675410</a>	AMC (RT Group)
S2308: Randomized Phase 3 study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma (PI: Kamdar/ 25-0024))	Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.	<a href="#">NCT06337318</a>	AMC
A Phase 1a/1b trial in relapsed/refractory T-cell non-hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, a fenretinide	Ages $>$ 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL	<a href="#">NCT04234048</a>	AMC



phospholipid suspension (12.5 mg/mL) for intravenous infusion (PI: Haverkos/24-0458)			
Phase 2 basket study of MK-2140 as monotherapy and in combination in aggressive and indolent B-cell malignancies (waveLINE-006) (PI: Bair/22-1252)	Ages $\geq$ 18; diagnosed aggressive or indolent B-cell malignancies; ECOG of $\leq$ 2	<a href="#">NCT05458297</a>	AMC
Phase Ib Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar/22-0939)	Ages $\geq$ 18; ECOG of $\leq$ 2	<a href="#">NCT05169515</a>	AMC
Phase 2 study of JCAR017 in adults with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) (PI: Kamdar/19-3011)	Ages $\geq$ 18; relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) histologically confirmed < 6 mos of screening, by local pathology; FL: Received at least 1 prior line; MZL: received 2+ prior lines; ECOG of 0 or 1	<a href="#">NCT04245839</a>	AMC
Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and adult patients with relapsed and/or refractory B-NHL (PI: Kamdar/21-2578)	Ages $\geq$ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	<a href="#">NCT05098613</a>	AMC
Phase 3 Study comparing the combination of beleodaq-CHOP or folotyn-COP to the CHOP regimen alone (24-2331)	Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	<a href="#">NCT06072131</a>	AMC
<b>Multiple Myeloma</b>			
A Phase 1, study of CB-011, a CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage Trial) (PI: Sherbenou/23-0376)	Ages $\geq$ 18; Diagnosed MM and evidence of PD based on IMWG criteria; ECOG of $\leq$ 1	<a href="#">NCT05722418</a>	AMC
A phase 1b/2, open-label study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory multiple myeloma remission (PI: Monge Urrea/24-2523)	Ages $\geq$ 18; Received at least three prior MM treatment lines of therapy; Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody	<a href="#">NCT05850234</a>	AMC
<b>Benign Heme</b>			
Phase 3 study of bomedemstat (MK-3543/IMG-7289) v. best available therapy (24-2052)	Essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea	<a href="#">NCT06079879</a>	AMC
<b>Allo Transplant/GVHD</b>			
A Phase 2, open-label, randomized, multicenter study to evaluate axatilimab in combination with	New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development	<a href="#">NCT06388564</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

ruxolitinib in participants with newly diagnosed chronic graft-versus-host disease (PI: Schwartz/24-1138)	Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy (Jagasia et al 2015).		
---	---	--	--

**Neuro-Oncology**  
**Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Clinic scheduler	-	Phone: 720-848-0300
Ana Lara-Rocha	<a href="mailto:Ana.Lararocha@ucHealth.org">Ana.Lararocha@ucHealth.org</a>	Phone: 720-848-9264
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Denise Damek, MD	<a href="mailto:Denise.damek@cuanschutz.edu">Denise.damek@cuanschutz.edu</a>	-

**Neuro-Oncology**

<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolamide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Newly diagnosed and recurrent GMB	<a href="https://clinicaltrials.gov/ct2/show/NCT05739942">NCT05739942</a>	AMC
Phase 1 study of perioperative vorasidenib (IDH1/2i) + pembrolizumab in recurrent or progressive enhancing IDH-1 mutant astrocytomas (24-0020)	IDH1 mutant astrocytomas/oligodendrogiomas recurrent or progressive enhancing	<a href="https://clinicaltrials.gov/ct2/show/NCT05484622">NCT05484622</a>	AMC
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma (19-0744)	Newly diagnosed and recurrent GBM	<a href="https://clinicaltrials.gov/ct2/show/NCT03970447">NCT03970447</a>	AMC,
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas (15-1747)	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT02523014">NCT02523014</a>	AMC
Protocol 10559 A Phase 2 study of erdafitinib in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusion (23-2578)	Recurrent and progressive gliomas	<a href="https://clinicaltrials.gov/ct2/show/NCT05859334">NCT05859334</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Phase 1, Expansion, Molecular Studies (POEMs)  
Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

**POEMs Studies**

<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
Phase I study of RO7673396 (pan-RASi) as single agent and in combination with other anticancer therapy (25-0860)	Advanced solid tumors with RAS mutations	<a href="#">NCT06884618</a>	AMC
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations Priority NSCLC	<a href="#">NCT06561685</a>	AMC (POEMs)
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	<a href="#">NCT03715933</a>	AMC (POEMs)
Phase 1 study of R07502175 (CCR8i) + pembrolizumab (22-1245)	NSCLC PD-L1 $\geq$ 50%, CPI naive	<a href="#">NCT05581004</a>	AMC (POEMs)
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	<a href="#">NCT05355701</a>	AMC (POEMs)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L melanoma 2L melanoma	<a href="#">NCT05533697</a>	AMC (POEMs)
ComBET: Phase 2 trial of ZEN-3694 (BETi) + talazoparib in advanced solid tumors (23-0145)	Advanced solid tumor prior PARPi +/- DDR (not BRCA1/2) mutation	<a href="#">NCT05327010</a>	AMC (POEMs)
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA kinase and helical mutations	<a href="#">NCT05768139</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer, NSCLC (adeno and Sq Cell)	<a href="#">NCT06014658</a>	AMC (POEMs)
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Metastatic breast, endometrial and platinum resistant ovarian	<a href="#">NCT06233942</a>	AMC (POEMs)
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload) (24-1562)	Part 2 Backfill: nsq-NSCLC and sq-NSCLC EGFR WT	<a href="#">NCT06384352</a>	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations NSCLC G12D/V only	<a href="#">NCT06447662</a>	AMC (POEMs)
Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, HNSCC	<a href="#">NCT04626635</a>	AMC (POEMs)
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

### Radiation Oncology Anschutz Medical Campus (AMC)

Nurse Navigator	Email	Phone
Pam Miranda	Pamela.miranda@ucHealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	Email	Phone
Christine Fisher, MD	Christine.fisher@cuanschutz.edu	
Rachel Rabinovitch, MD	Rachel.Rabinovitch@cuanschutz.edu	

### Radiation Oncology-Breast Cancer

Study	Patients	NCT#	Sites
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0M0 breast cancer following surgery (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="#">NCT03488693</a>	AMC, CCMC, HRH, LT
DEBRA (BR007): Phase 3 trial of de-escalation of RT in stage I HR+HER2- breast cancer (21-4582)	Stage I, HR+, HER2- breast cancer with Oncotype RS $\leq$ 18	<a href="#">NCT04852887</a>	AMC, CCMC, HRH

### Radiation Oncology- Genitourinary Cancer

NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	<a href="#">NCT05053152</a>	AMC, HRH
NRG GU010: Genomic risk stratification for unfavorable intermed risk localized prostate cancer (22-0175)	Localized prostate cancer unfavorable intermediate risk	<a href="#">NCT05050084</a>	AMC

### Radiation Oncology - Lymphoma

Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (24-2065)	Newly diagnosed Stage I and II classic hodgkins lymphoma	<a href="#">NCT05675410</a>	AMC
--	--	-----------------------------	-----

### Radiation Oncology -Lung Cancer

MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung (20-0359)	Small-Cell Lung Cancer	<a href="#">NCT04155034</a>	AMC, HRH
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	<a href="#">NCT05624996</a>	AMC, LT, HRH
DURABLE: Delayed or upfront brain Radiotherapy (24-1615)	naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and ALK rearrangement	<a href="#">NCT05987644</a>	AMC

### Radiation Oncology-Pancreatic Cancer

#### No currently active studies

### Radiation Oncology –Neuro Oncology

Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Newly diagnosed and recurrent GMB	<a href="#">NCT05739942</a>	AMC
--	-----------------------------------	-----------------------------	-----

### Radiation Oncology-Multiple Cancer Types



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

NRG-BN013: PHASE 3 study of single fraction SRS for versus FSRS for intact brain metastases (24-2477)	Non-small cell lung cancer Melanoma Breast cancer Renal cell carcinoma Gastrointestinal cancer at least 1 and up to 8 total intact brain metastases and at least 1 of the up to 8 lesions must be a lesion with a maximum diameter of $\geq 1.0$ cm and $\leq 3.0$ cm	<a href="#">NCT06500455</a>	AMC
---	--	-----------------------------	-----



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Sarcoma**  
**Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@ucHealth.org	Phone: 720-848-0201 Fax: 720-848-0160
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	

**Sarcoma**

<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
Phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (25-0217)	Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas	<a href="#">NCT05711615</a>	AMC
STRASS 2 (EA7211): Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma (23-1625)	High risk retroperitoneal sarcoma (LPS/LMS)	<a href="#">NCT04031677</a>	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas (24-2043)	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	<a href="#">NCT06422806</a>	AMC
Phase 1/2 study of ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated subjects with leiomyosarcoma (23-1728)	Leiomyosarcoma	<a href="#">NCT05712694</a>	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (24-1378)	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	<a href="#">NCT06127407</a>	AMC
A Phase I/Ib Study of losartan in combination with sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (18-2740)	Osteosarcoma	<a href="#">NCT03900793</a>	CHCO, AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	<a href="#">NCT03715933</a>	AMC (POEMs)
A phase II study on efficacy and tolerability of weekly doxorubicin in elderly patients (24-0118)	Advanced or Metastatic Leiomyosarcoma of Soft Tissue	<a href="#">NCT07125183</a>	AMC
Phase 1/2, open-label, dose escalation and expansion study of ADCE-D01, a humanized anti-human uPARAP antibody linked to a topoisomerase I inhibitor (24-2281)	Metastatic and/or Unresectable Soft Tissue Sarcoma	<a href="#">NCT06797999</a>	AMC
Multi-cohort, open-label, Phase 1/2 study of DCC-3009 in participants with gastrointestinal stromal tumors (GIST) (24-2282)	GIST	<a href="#">NCT06630234</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Phase 3 study of ivosidenib (CHONQUER study) (24-1378)	Untreated or 1 prior line, locally advanced or metastatic conventional chondrosarcoma, IDH1 mutation	<a href="#">NCT06127407</a>	AMC
A phase 1/2 trial of neoadjuvant ADI-PEG 20 in combination with ifosfamide and radiotherapy in soft tissue sarcoma (STS) (24-1884)	Soft tissue sarcoma	<a href="#">NCT05813327</a>	AMC
Phase 3 study of lurbinectedin + doxorubicin v. doxorubicin (SaLuDo) (25-0027)	1L metastatic leiomyosarcoma	<a href="#">NCT06088290</a>	AMC
Phase 1 study of ziftomenib + imatinib	GIST after imatinib failure	<a href="#">NCT06655246</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

**Thoracic (Lung) Oncology**  
**Anschutz Medical Campus (AMC)**

<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Courtney Sorensen, RN	Courtney.thoutt@ucHealth.org	Phone: 720-848-2962 Fax: 720-848-0360
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	

**Early-Stage NSCLC**

<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC (22-1484)	Stage IB-III NSCLC ALK fusion, (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT) (Only ALK Fusion Cohort open)	<a href="#">NCT04302025</a>	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	<a href="#">NCT05624996</a>	AMC, LT, HRH (RT Group)

**1<sup>st</sup> Line Metastatic NSCLC**

Phase 3 study of vonescimab v. pembrolizumab (25-0500)	First line Metastatic NSCLC with High PD-L1 expression	<a href="#">NCT06767514</a>	AMC
Study of response of bony metastasis for patients on TKI or systemic treatment (19-0392)	NSCLC with completed molecular testing; receiving standard of care TKI or systemic therapy for actionable driver	<a href="#">NCT03958565</a>	AMC, LT
Phase 1 study of R07502175 (CCR8i) + pembrolizumab (22-1245)	NSCLC PD-L1 $\geq$ 50%, CPI naive	<a href="#">NCT05581004</a>	AMC (POEMS)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50%	<a href="#">NCT05533697</a>	AMC (POEMS)
Phase 1/2 study of REGN7075 (EGFR $\times$ CD28 bispecific ab) + cemiplimab (24-2232)		<a href="#">NCT04626635</a>	AMC (POEMS)

**EGFR mutant NSCLC**

LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab (23-0936)	Metastatic NSCLC EGFR mutant with MET amplification as resistance	<a href="#">NCT05642572</a>	AMC
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC (23-2288)	Metastatic NSCLC with EGFR mutation	<a href="#">NCT05983432</a>	AMC
Phase 1b/2 study of BG-60366 (EGFR CDAC protein degrader) for EGFRm NSCLC patients (25-0436)	Metastatic NSCLC with EGFR mutation	<a href="#">NCT06685718</a>	AMC

**ALK, ROS1, or RET rearranged NSCLC**

NVL-655 EAP: Expanded access program for NVL-655 (novel ALK TKI) (22-0814)	Metastatic NSCLC with ALK	<a href="#">NCT05384626</a>	AMC
Phase 1/2 study of amivantamab in metastatic NSCLC with ALK, ROS1 or RET gene fusions (22-1450)	Previously treated advanced NSCLC with ALK, ROS1, or RET gene fusions	<a href="#">NCT05845671</a>	AMC



Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Expanded access treatment of zidesamtinib (NVL-520) (25-0792)	Advanced ROS1+ NSCLC or other ROS1+ solid tumors	<a href="#">NCT06797362</a>	AMC
<b>MET or HER2 altered NSCLC</b>			
SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC (24-0486)	MET exon skip metastatic NSCLC	<a href="#">NCT06031688</a>	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC	<a href="#">NCT05983432</a>	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced cancers harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)
<b>KRAS or BRAF altered NSCLC</b>			
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations, NSCLC G12D/V	<a href="#">NCT06447662</a>	AMC (POEMs)
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation</b>			
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload) (24-1562)	NSCLC EGFR WT	<a href="#">NCT06384352</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (24-2430)	Metastatic NSCLC (adeno and SCC)	<a href="#">NCT06014658</a>	AMC (POEMs)
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules</b>			
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations	<a href="#">NCT06561685</a>	AMC (POEMs)
<b>Small Cell Lung Cancer</b>			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung (20-0359)	Small-Cell Lung Cancer	<a href="#">NCT04155034</a>	AMC, HRH
Harpoon: Phase 1 / 2 study of HPN328-4001, Trispecific T-cell activating construct to CD3, HAS, and DLL3. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (21-2992)	Metastatic SCLC	<a href="#">NCT04471727</a>	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC and SCLC	<a href="#">NCT05983432</a>	AMC
<b>Mesothelioma and Thymic Malignancies</b>			
AZ Evolve: Phase 3 study of volrustomig (PD1/CTLA4 bispecific) + chemotherapy vs investigators choice (24-0442)	unresectable, untreated mesothelioma	<a href="#">NCT06097728</a>	AMC



Satellite Site Contacts		
	Physician Leads	Nurse Navigators
CCMC	Scott Kono, MD 720-550-0270 (cell) ( <a href="mailto:Scott.Kono@CUAnschutz.edu">Scott.Kono@CUAnschutz.edu</a> )	Lanie Wolff ( <a href="mailto:lanie.wolff@ucHealth.org">lanie.wolff@ucHealth.org</a> ) 720-516-9254
HRH	Elaine Lam, MD ( <a href="mailto:Elaine.Lam@CUAnschutz.edu">Elaine.Lam@CUAnschutz.edu</a> )	Tera Stewart ( <a href="mailto:Tera.Stewart@CUAnschutz.edu">Tera.Stewart@CUAnschutz.edu</a> ) and Kara Ickler ( <a href="mailto:Kara.Ickler@CUAnschutz.edu">Kara.Ickler@CUAnschutz.edu</a> )
LT	Corbin Eule, MD ( <a href="mailto:Corbin.Eule@CUAnschutz.edu">Corbin.Eule@CUAnschutz.edu</a> )	Crystal Stribling ( <a href="mailto:CrystalD.Stribling@ucHealth.org">CrystalD.Stribling@ucHealth.org</a> )

Common Eligibility Criteria for Clinical Trials	
<b>Performance Status</b>	ECOG 0-1 Karnofsky Performance Status $\geq 60$
<b>Age</b>	Age $\geq 18$ years (ask for sarcoma trials)
<b>Measurable disease</b>	<b>Lesions that can be accurately measured in at least one dimension</b> with a minimum size requirement: <ul style="list-style-type: none"><li>• <b>For CT or MRI scans:</b><ul style="list-style-type: none"><li>◦ The lesion must be <b><math>\geq 10</math> mm</b> in its longest diameter.</li><li>◦ For lymph nodes, the short axis must be <b><math>\geq 15</math> mm</b> to be considered measurable.</li></ul></li><li>• <b>For physical exam or clinical measurement:</b><ul style="list-style-type: none"><li>◦ The lesion must be <b><math>\geq 10</math> mm</b> in its longest dimension and should be measurable with a caliper or ruler.</li></ul></li><li>• <b>For ultrasound:</b><ul style="list-style-type: none"><li>◦ Lesions can only be considered measurable if they are confirmed by CT or MRI measurements.</li></ul></li></ul> <b>Non-Measurable Lesions:</b> <ul style="list-style-type: none"><li>• Lesions that do not meet the criteria above are classified as <b>non-measurable</b>.</li><li>• Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are <b>not</b> considered measurable disease.</li></ul>
<b>Adequate organ and bone marrow function</b>	<b>Bone marrow:</b> ANC $\geq 1.5$ , Hgb $\geq 9.0$ (without recent transfusion), platelets $\geq 100$ (without recent transfusion). <b>Hepatic:</b> AST and ALT $< 2 \times$ ULN, bilirubin $< 2.0$ . <b>Renal:</b> CrCl $\geq 50$ ml/min. <b>Cardiovascular:</b> No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months. <b>Pulmonary:</b> History of ILD requiring steroids (protocol dependent). <b>Neurologic:</b> If brain metastases are present, they must have been treated and not progressing.